Zacks Investment Research lowered shares of Hill-Rom Holdings Inc (NYSE:HRC) from a buy rating to a hold rating in a research report report published on Tuesday morning.

According to Zacks, “Hill-Rom exited fiscal 2017 on a strong note with fourth-quarter earnings and revenues beating the Zacks Consensus Estimate. The company saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom is currently focused on gaining traction in the untapped international market on successful execution of the company’s strategy, courtesy its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted and operating margin buoys optimism. However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.Overall, Hill-Rom has underperformed the broader industry in the last six months.”

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus lifted their target price on Hill-Rom Holdings from $84.00 to $85.00 and gave the company a buy rating in a research report on Monday. ValuEngine cut Hill-Rom Holdings from a buy rating to a hold rating in a research report on Saturday. BidaskClub upgraded Hill-Rom Holdings from a sell rating to a hold rating in a research report on Sunday, August 6th. Needham & Company LLC decreased their target price on Hill-Rom Holdings from $95.00 to $93.00 and set a buy rating on the stock in a research report on Friday, July 28th. Finally, Barclays PLC boosted their price target on Hill-Rom Holdings from $86.00 to $90.00 and gave the stock an overweight rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $88.57.

Hill-Rom Holdings (NYSE HRC) traded down $0.28 during trading on Tuesday, reaching $78.19. The company’s stock had a trading volume of 419,190 shares, compared to its average volume of 509,273. Hill-Rom Holdings has a 1 year low of $50.50 and a 1 year high of $84.65. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. The company has a market capitalization of $5,165.05, a PE ratio of 20.31, a PEG ratio of 1.64 and a beta of 1.19.

Hill-Rom Holdings (NYSE:HRC) last released its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.05. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. During the same quarter in the previous year, the business posted $1.18 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. research analysts forecast that Hill-Rom Holdings will post 4.26 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Hill-Rom Holdings Inc (HRC) Lowered to Hold at Zacks Investment Research” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/08/hill-rom-holdings-inc-hrc-lowered-to-hold-at-zacks-investment-research.html.

In related news, SVP Andreas G. Frank sold 3,940 shares of Hill-Rom Holdings stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total value of $306,689.60. Following the transaction, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at $1,300,005.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Andreas G. Frank sold 6,870 shares of Hill-Rom Holdings stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $77.48, for a total value of $532,287.60. Following the completion of the transaction, the senior vice president now directly owns 16,701 shares in the company, valued at $1,293,993.48. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Independent Portfolio Consultants Inc. lifted its stake in shares of Hill-Rom Holdings by 171.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock worth $107,000 after acquiring an additional 849 shares during the period. Seven Eight Capital LP acquired a new position in shares of Hill-Rom Holdings in the second quarter worth approximately $127,000. Acrospire Investment Management LLC lifted its stake in shares of Hill-Rom Holdings by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock worth $158,000 after acquiring an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hill-Rom Holdings by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 204 shares during the period. Finally, Citigroup Inc. lifted its stake in shares of Hill-Rom Holdings by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after acquiring an additional 433 shares during the period. 81.92% of the stock is currently owned by institutional investors.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.